IMAB – I-Mab ADR
I-MABIMAB
$2.42Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $197,617,936.00
EPSttm : -0.55
I-MAB
$2.42
5.84%$0.15Float Short %
0.48
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
EPS Last/This Y
0.08
EPS This/Next Y
-0.11
Price
2.4
Target Price
5.6
Analyst Recom
1
Performance Q
187.65
Relative Volume
1.11
Beta
1.4
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | IMAB | 1.28 | 0.00 | 0.00 | 385 |
| 2025-06-03 | IMAB | 1.88 | 0.00 | 0.13 | 411 |
| 2025-06-04 | IMAB | 1.79 | 0.07 | 0.13 | 693 |
| 2025-06-05 | IMAB | 2.22 | 0.08 | 0.02 | 643 |
| 2025-06-06 | IMAB | 2.45 | 0.07 | 0.01 | 807 |
| 2025-06-09 | IMAB | 2.77 | 0.06 | 0.06 | 906 |
| 2025-06-10 | IMAB | 2.65 | 0.08 | 0.12 | 891 |
| 2025-06-11 | IMAB | 2.46 | 0.09 | 0.02 | 1027 |
| 2025-06-12 | IMAB | 2.6 | 0.08 | 0.03 | 1109 |
| 2025-06-13 | IMAB | 2.48 | 0.08 | 0.03 | 1109 |
| 2025-06-16 | IMAB | 2.5 | 0.08 | 0.21 | 1114 |
| 2025-06-17 | IMAB | 2.46 | 0.04 | 1.08 | 1053 |
| 2025-06-18 | IMAB | 2.33 | 0.04 | 0.00 | 1064 |
| 2025-06-20 | IMAB | 2.45 | 0.04 | 0.07 | 1073 |
| 2025-06-23 | IMAB | 2.46 | 0.03 | 0.00 | 873 |
| 2025-06-24 | IMAB | 2.38 | 0.03 | 0.00 | 873 |
| 2025-06-25 | IMAB | 2.71 | 0.03 | 0.01 | 873 |
| 2025-06-26 | IMAB | 2.02 | 0.03 | 0.00 | 927 |
| 2025-06-27 | IMAB | 2.56 | 0.06 | 0.46 | 997 |
| 2025-06-30 | IMAB | 2.42 | 0.23 | 0.68 | 1450 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | IMAB | 1.29 | - | - | -0.17 |
| 2025-06-03 | IMAB | 1.87 | - | - | -0.17 |
| 2025-06-04 | IMAB | 1.79 | - | - | -0.17 |
| 2025-06-05 | IMAB | 2.29 | - | - | -0.17 |
| 2025-06-06 | IMAB | 2.44 | - | - | -0.17 |
| 2025-06-09 | IMAB | 2.80 | - | - | -0.17 |
| 2025-06-10 | IMAB | 2.65 | - | - | -0.17 |
| 2025-06-11 | IMAB | 2.49 | - | - | -0.17 |
| 2025-06-12 | IMAB | 2.58 | - | - | -0.17 |
| 2025-06-13 | IMAB | 2.49 | - | - | -0.17 |
| 2025-06-16 | IMAB | 2.52 | - | - | -0.17 |
| 2025-06-17 | IMAB | 2.51 | - | - | -0.17 |
| 2025-06-18 | IMAB | 2.33 | - | - | -0.17 |
| 2025-06-20 | IMAB | 2.50 | - | - | -0.17 |
| 2025-06-23 | IMAB | 2.45 | - | - | -0.17 |
| 2025-06-24 | IMAB | 2.38 | - | - | -0.17 |
| 2025-06-25 | IMAB | 2.73 | - | - | -0.17 |
| 2025-06-26 | IMAB | 2.02 | - | - | -0.17 |
| 2025-06-27 | IMAB | 2.55 | - | - | -0.20 |
| 2025-06-30 | IMAB | 2.40 | - | - | -0.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-03 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-04 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-05 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-06 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-09 | IMAB | 0.00 | -44.04 | 0.36 |
| 2025-06-11 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-12 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-13 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-16 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-17 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-18 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-19 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-20 | IMAB | 0.00 | -44.04 | 0.35 |
| 2025-06-24 | IMAB | 0.00 | -42.89 | 0.35 |
| 2025-06-25 | IMAB | 0.00 | -42.89 | 0.35 |
| 2025-06-26 | IMAB | 0.00 | -42.89 | 0.48 |
| 2025-06-27 | IMAB | 0.00 | -42.89 | 0.48 |
| 2025-06-30 | IMAB | 0.00 | -42.89 | 0.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
-42.89
Beta
1.4
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
16
Growth Score
19
Sentiment Score
86
Actual DrawDown %
97.2
Max Drawdown 5-Year %
-99.3
Target Price
5.6
P/E
Forward P/E
PEG
P/S
P/B
1
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.2
EPS Next Y. (Est.)
-0.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.11
Return on Equity vs Sector %
-28.4
Return on Equity vs Industry %
-9.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading